Dream Pharma signs exclusive license agreement with Addrenex

Published: 2009-08-12 06:56:00

Updated: 2009-08-12 06:56:00

Dream Pharma, a division of Hanwha Group, said on August 4 that it signed an exclusive licensing agreement with the US-based Addrenex Pharmaceuticals to market a sustained-release formulation of Clonicel (clonidine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK